Key facts
- Life Biosciences’s last known valuation is $500.0M (Jan 2019).
- It has raised $255.2M across 3 recorded rounds; the latest was Early Stage VC ($31.0M) in Nov 2025.
- Notable investors include Gaingels, Alpha Wave Global, The Venture Collective, LeFrak, Globalive Capital — 16 tracked in total.
- Life Biosciences has filed 4 Form Ds with the SEC since 2019, most recently Jun 2021 ($74.8M sold to 35 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Life Biosciences
Funding rounds
3 roundsAbout Life Biosciences
Developer of drug therapies designed to improve the lives of people as they age. The company's drugs help to combat the eight pathways of age-related decline, and its work addresses health decline due to aging as a systemic breakdown of the body, rather than a series of isolated events and conditions, enabling senior citizens to tackle age-related diseases to extend healthy life spans.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2017
- Employees
- 26
- Website
- lifebiosciences.com/
- Ownership
- Privately Held (backing)
Life Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Life Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Life Biosciences in its N-PORT filings yet. We sweep new filings monthly.